Jun 20, 2014

Stemedica plans to initiate Phase IIa 70-patient Alzheimer’s disease trial this year – executive

Another Stemedica subsidiary, CardioCell, has an exclusive, worldwide license for IV-administered allogeneic ischemia-tolerant mesenchymal stem cells (itMSCs). CardioCell manages trials in acute myocardial infarction, chronic heart failure and is exploring the use of the itMSCs in peripheral artery disease, according to the CardioCell website. SUBSCRIPTION REQUIRED TO READ FULL ARTICLE